Matthew D Zinn1, Michael J Wallendorf2, Kathleen E Simpson3, Ashley D Osborne4, James K Kirklin5, Charles E Canter3. 1. Department of Pediatrics, Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA; Department of Pediatric Cardiology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Electronic address: matthew.zinn@chp.edu. 2. Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA. 3. Department of Pediatrics, Division of Cardiology, Washington University School of Medicine, St. Louis, Missouri, USA; Department of Pediatric Cardiology, Saint Louis Children's Hospital, St. Louis, Missouri, USA. 4. Department of Pediatrics, Division of Cardiology, Washington University School of Medicine, St. Louis, Missouri, USA. 5. Department of Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
BACKGROUND: The effect of age at transplant on rejection detected by routine surveillance biopsy (RSB) in pediatric heart transplant (HT) recipients is unknown. We hypothesized there would be low diagnostic yield and decreased prevalence of rejection detected on RSB in infants (age <1 year) when compared with children (age 1 to 9 years) and adolescents (age 10 to 18 years). METHODS: We utilized Pediatric Heart Transplant Study (PHTS) data from 2010 to 2013 to analyze moderate-to-severe (ISHLT Grade 2R/3R) cellular rejection (MSR) detected only on RSB (RSBMSR). RESULTS: RSB detected 280 of 343 (81.6%) episodes of MSR. RSBMSR was detected in all age groups even >5 years after HT. Infant RSBMSR had a greater proportion (p = 0.0025) occurring >5 years after HT (39.2 vs 18.4 vs 10.8%) and a lower proportion (p = 0.0009) occurring in the first year after HT (25.5 vs 60.6 vs 51.7%) compared with children and adolescents, respectively. Freedom from RSBMSR was 87 ± 7% in infants, 76 ± 6% in children and 73 ± 7% in adolescents 4 years after HT. In 1-year survivors who had RSBMSR in the first year after HT, the risk of RSBMSR occurring in Years 2 to 4 was significantly (p < 0.0001) greater than patients without RSBMSR in the first year (hazard ratio 21.28, 95% confidence interval 10.87 to 41.66), regardless of recipient age. CONCLUSIONS: RSBMSR exists in all age groups after pediatric HT with long-term follow-up. The prevalence in infant recipients is highest >5 years after HT. Those with RSBMSR in the first year after HT are at a high risk for recurrent rejection regardless of age at HT.
BACKGROUND: The effect of age at transplant on rejection detected by routine surveillance biopsy (RSB) in pediatric heart transplant (HT) recipients is unknown. We hypothesized there would be low diagnostic yield and decreased prevalence of rejection detected on RSB in infants (age <1 year) when compared with children (age 1 to 9 years) and adolescents (age 10 to 18 years). METHODS: We utilized Pediatric Heart Transplant Study (PHTS) data from 2010 to 2013 to analyze moderate-to-severe (ISHLT Grade 2R/3R) cellular rejection (MSR) detected only on RSB (RSBMSR). RESULTS:RSB detected 280 of 343 (81.6%) episodes of MSR. RSBMSR was detected in all age groups even >5 years after HT. InfantRSBMSR had a greater proportion (p = 0.0025) occurring >5 years after HT (39.2 vs 18.4 vs 10.8%) and a lower proportion (p = 0.0009) occurring in the first year after HT (25.5 vs 60.6 vs 51.7%) compared with children and adolescents, respectively. Freedom from RSBMSR was 87 ± 7% in infants, 76 ± 6% in children and 73 ± 7% in adolescents 4 years after HT. In 1-year survivors who had RSBMSR in the first year after HT, the risk of RSBMSR occurring in Years 2 to 4 was significantly (p < 0.0001) greater than patients without RSBMSR in the first year (hazard ratio 21.28, 95% confidence interval 10.87 to 41.66), regardless of recipient age. CONCLUSIONS:RSBMSR exists in all age groups after pediatric HT with long-term follow-up. The prevalence in infant recipients is highest >5 years after HT. Those with RSBMSR in the first year after HT are at a high risk for recurrent rejection regardless of age at HT.
Authors: Clifford Chin; David C Naftel; Tajinder P Singh; Elizabeth D Blume; Helen Luikart; Daniel Bernstein; Pat Gamberg; James K Kirklin; W Robert Morrow Journal: J Heart Lung Transplant Date: 2004-02 Impact factor: 10.247
Authors: Anne I Dipchand; Richard Kirk; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Fabienne Dobbels; Lars H Lund; Axel O Rahmel; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2013-10 Impact factor: 10.247
Authors: Jill E Ibrahim; Stuart C Sweet; Mindee Flippin; Catherine Dent; Eric Mendelhoff; Charles B Huddleston; Kathryn Trinkhaus; Charles E Canter Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: J K Kirklin; D C Naftel; R C Bourge; C White-Williams; J B Caulfield; M R Tarkka; W L Holman; G L Zorn Journal: Circulation Date: 1992-11 Impact factor: 29.690
Authors: David N Rosenthal; Clifford Chin; Kyra Nishimura; Stanton B Perry; Robert C Robbins; Bruce Reitz; Daniel Bernstein; Jeffrey A Feinstein Journal: J Heart Lung Transplant Date: 2004-03 Impact factor: 10.247
Authors: S H Kubo; D C Naftel; R M Mills; J O'Donnell; R J Rodeheffer; G B Cintron; J L Kenzora; R C Bourge; J K Kirklin Journal: J Heart Lung Transplant Date: 1995 May-Jun Impact factor: 10.247
Authors: V R Zales; S Crawford; C L Backer; E Pahl; C L Webb; P Lynch; C Mavroudis; D W Benson Journal: J Am Coll Cardiol Date: 1994-03-01 Impact factor: 24.094
Authors: Christopher A Miller; James E Fildes; Simon G Ray; Helen Doran; Nizar Yonan; Simon G Williams; Matthias Schmitt Journal: Heart Date: 2012-12-20 Impact factor: 5.994
Authors: David M Peng; Victoria Y Ding; Seth A Hollander; Tigran Khalapyan; John C Dykes; David N Rosenthal; Christopher S Almond; Charlotte Sakarovitch; Manisha Desai; Doff B McElhinney Journal: Pediatr Transplant Date: 2018-12-01